Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches

M Sekhoacha, K Riet, P Motloung, L Gumenku… - Molecules, 2022 - mdpi.com
Simple Summary Prostate cancer affects men of all racial and ethnic groups and leads to
higher rates of mortality in those belonging to a lower socioeconomic status due to late …

Oxidative stress in prostate hyperplasia and carcinogenesis

UK Udensi, PB Tchounwou - Journal of Experimental & Clinical Cancer …, 2016 - Springer
Prostatic hyperplasia (PH) is a common urologic disease that affects mostly elderly men. PH
can be classified as benign prostatic hyperplasia (BPH), or prostate cancer (PCa) based on …

Reduction of circular RNA Foxo3 promotes prostate cancer progression and chemoresistance to docetaxel

Z Shen, L Zhou, C Zhang, J Xu - Cancer letters, 2020 - Elsevier
Dysregulation of circular RNA Foxo3 (circFoxo3) has been reported to be involved in breast
cancer and non-small lung cancer progression. However, little is known about the role of …

The utility of urine-circulating miRNAs for detection of prostate cancer

K Stuopelyte, K Daniunaite, A Bakavicius… - British journal of …, 2016 - nature.com
Background: In this paper, the utility of urine-circulating microRNAs (miRNAs) as the
potential biomarker of prostate cancer (PCa), the second most prevalent male cancer …

[HTML][HTML] Prostate cancer proteomics: Current trends and future perspectives for biomarker discovery

CP Tanase, E Codrici, ID Popescu, S Mihai, AM Enciu… - Oncotarget, 2017 - ncbi.nlm.nih.gov
The clinical and fundamental research in prostate cancer-the most common urological
cancer in men-is currently entering the proteomic and genomic era. The focus has switched …

Proteomic analysis of prostate cancer FFPE samples reveals markers of disease progression and aggressiveness

V Lygirou, K Fasoulakis, R Stroggilos, M Makridakis… - Cancers, 2022 - mdpi.com
Simple Summary Prostate cancer (PCa) is the second most frequently diagnosed type of
cancer in men. The lack of tools for accurate risk assessment is causing over-treatment of …

Brachytherapy future directions

JAM Cunha, R Flynn, C Bélanger, C Callaghan… - Seminars in radiation …, 2020 - Elsevier
Brachytherapy has advanced dramatically in the last decade due largely to improvements in
applicators, imaging, treatment planning, and use of clinical trials. In addition, current …

Circular RNA Foxo3: a promising cancer-associated biomarker

T Yang, Y Li, F Zhao, L Zhou, R Jia - Frontiers in Genetics, 2021 - frontiersin.org
Circular RNAs (circRNAs) are a class of novel non-coding RNAs (ncRNAs). Emerging
evidence demonstrates that circRNAs play crucial roles in many biological processes by …

[HTML][HTML] Urinary microRNA-1913 to microRNA-3659 expression ratio as a non-invasive diagnostic biomarker for prostate cancer

YJ Byun, XM Piao, P Jeong, HW Kang… - … and Clinical Urology, 2021 - ncbi.nlm.nih.gov
Purpose MicroRNAs (miRNAs) are small non-coding RNAs and are involved in the
development, proliferation, and pathogenesis of prostate cancer (PCa). Urinary miRNAs are …

Potential plasma microRNAs signature miR-190b-5p, miR-215-5p and miR-527 as non-invasive biomarkers for prostate cancer

MM Khan, M Serajuddin, M Bharadwaj - Biomarkers, 2023 - Taylor & Francis
Abstract Background Prostate cancer (PCa) is the most prevalent (20%) pathological cancer
among males globally. MicroRNAs (miRNAs) are short (19–22 nucleotide), conserved …